{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T17:30:12Z","timestamp":1767634212093,"version":"3.48.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020309","name":"KARL STORZ","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020309","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Combined criteria have been used in many facets of urologic surgical care in the management of urological cancer. We aimed to validate the prognostic ability of a pentafecta related to the outcomes of radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\u00a0Data were obtained from the Clinical Research Office of the Endourology Society Urothelial Carcinomas of the Upper Tract (CROES-UTUC) registry, a prospective multinational database. Non-metastatic UTUC patients treated with RNU were included. We adopted a pentafecta criteria of (1) negative surgical margin; (2) en\u00a0bloc resection of the bladder cuff; (3) absence of major complications; (4) template-based lymph node dissection performed per European Association of Urology guidelines; and (5) absence of recurrence (urothelial and\/or distant recurrence) within 12 months. Outcomes were pentafecta achievement rates and oncological outcomes, including overall survival (OS) and recurrence-free survival (RFS). Kaplan\u2013Meier survival analyses with log-rank were performed on survival outcomes. Multivariate Cox regression was performed to identify confounders, and logistic regression was performed to identify factors that confounded the pentafecta achievement rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      \u00a0Overall, 1049 cases were analyzed, and pentafecta was achieved in 504 patients (48.0%). Baseline characteristics were comparable between those who achieved pentafecta versus those who did not. Pentafecta achievement was associated with OS advantage (hazard ratio [HR] 0.586,\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      =\u00a00.024) and RFS advantage (HR 0.291,\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      =\u00a00.001). Multivariate Cox regression analysis identified that only pentafecta achievement and advanced T stage were independent predictors of RFS and OS. A ureteric location (compared with pelvicalyceal tumor) (odds ratio [OR] 0.424,\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      =\u00a00.002), multifocality (OR 0.191,\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      &lt;\u00a00.001) and open RNU (OR 0.661,\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      =\u00a00.010) were predictors of pentafecta non-achievement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We validated a pentafecta that gauged surgical quality for RNU. Quality-of-care metrics should be promoted to unify surgical outcomes in UTUC management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18411-5","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T17:32:09Z","timestamp":1759599129000},"page":"1848-1857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radical Nephroureterectomy Pentafecta as a Predictor of Upper Tract Urothelial Carcinoma Outcomes Following Radical Surgery"],"prefix":"10.1245","volume":"33","author":[{"given":"Chris Ho-Ming","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan Ching-Ho","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Ka-Wai","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongda","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Laguna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"de la Rosette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"18411_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2147\/CMAR.S445529","volume":"16","author":"E Nally","year":"2024","unstructured":"Nally E, Young M, Chauhan V, Wells C, Szabados B, Powles T, et al. Upper tract urothelial carcinoma (UTUC): prevalence, impact and management challenge. Cancer Manag Res. 2024;16:467\u201375.","journal-title":"Cancer Manag Res."},{"issue":"1","key":"18411_CR2","first-page":"96","volume":"35","author":"AH Zahalka","year":"2025","unstructured":"Zahalka AH, Margulis V. Minimizing overtreatment and maximizing oncologic outcomes in upper tract urothelial carcinoma. Curr Opin Urol. 2025;35(1):96\u2013102.","journal-title":"Curr Opin Urol."},{"issue":"1","key":"18411_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupret","year":"2023","unstructured":"Roupret M, Seisen T, Birtle AJ, Capoun O, Comperat EM, Dominguez-Escrig JL, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol. 2023;84(1):49\u201364.","journal-title":"Eur Urol."},{"issue":"6","key":"18411_CR4","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00345-018-2506-1","volume":"37","author":"A Upfill-Brown","year":"2019","unstructured":"Upfill-Brown A, Lenis AT, Faiena I, Salmasi AH, Johnson DC, Pooli A, et al. Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines. World J Urol. 2019;37(6):1157\u201364.","journal-title":"World J Urol."},{"issue":"1","key":"18411_CR5","first-page":"1","volume":"22","author":"J Raman","year":"2020","unstructured":"Raman J, Shore ND. Management of low-grade upper tract urothelial carcinoma: an unmet need. Rev Urol. 2020;22(1):1\u20138.","journal-title":"Rev Urol."},{"issue":"11","key":"18411_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.ejso.2016.08.008","volume":"42","author":"D Fang","year":"2016","unstructured":"Fang D, Seisen T, Yang K, Liu P, Fan X, Singla N, et al. A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol. 2016;42(11):1625\u201335.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"18411_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109593","volume":"51","author":"JW Butterworth","year":"2025","unstructured":"Butterworth JW, Boshier PR, Mavroveli S, Reynolds JV, Kim YW, Hanna GB. A proposed framework of strategies to overcome challenges to surgical quality assurance in oncology trials (SQA-Onc). Eur J Surg Oncol. 2025;51(5):109593.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"18411_CR8","doi-asserted-by":"publisher","first-page":"15835","DOI":"10.1038\/s41598-023-43092-z","volume":"13","author":"T Bejrananda","year":"2023","unstructured":"Bejrananda T, Takahara K, Sowanthip D, Motonaga T, Yagi K, Nakamura W, et al. Comparing pentafecta outcomes between nerve sparing and non nerve sparing robot-assisted radical prostatectomy in a propensity score-matched study. Sci Rep. 2023;13(1):15835.","journal-title":"Sci Rep."},{"issue":"6 Pt 2","key":"18411_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1464-410X.2011.10521.x","volume":"108","author":"VR Patel","year":"2011","unstructured":"Patel VR, Abdul-Muhsin HM, Schatloff O, Coelho RF, Valero R, Ko YH, et al. Critical review of \u201cpentafecta\u201d outcomes after robot-assisted laparoscopic prostatectomy in high-volume centres. BJU Int. 2011;108(6 Pt 2):1007\u201317.","journal-title":"BJU Int."},{"issue":"1","key":"18411_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.juro.2012.09.042","volume":"189","author":"AJ Hung","year":"2013","unstructured":"Hung AJ, Cai J, Simmons MN, Gill IS. Trifecta in partial nephrectomy. J Urol. 2013;189(1):36\u201342.","journal-title":"J Urol."},{"issue":"4","key":"18411_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1590\/s1677-5538.ibju.2021.0095","volume":"48","author":"N Bai","year":"2022","unstructured":"Bai N, Qi M, Shan D, Liu S, Na T, Chen L. Trifecta achievement in patients undergoing partial nephrectomy: a systematic review and meta-analysis of predictive factors. Int Braz J Urol. 2022;48(4):625\u201336.","journal-title":"Int Braz J Urol."},{"issue":"3","key":"18411_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151738","volume":"11","author":"DK Kim","year":"2016","unstructured":"Kim DK, Kim LH, Raheem AA, Shin TY, Alabdulaali I, Yoon YE, et al. Comparison of trifecta and pentafecta outcomes between T1a and T1b renal masses following robot-assisted partial nephrectomy (RAPN) with minimum one year follow up: can RAPN for T1b renal masses be feasible? PLoS One. 2016;11(3):e0151738.","journal-title":"PLoS One."},{"key":"18411_CR13","doi-asserted-by":"crossref","unstructured":"Konig F, Grossmann NC, Soria F, D'Andrea D, Juvet T, Potretzke A, et al. Pentafecta for radical nephroureterectomy in patients with high-risk upper tract urothelial carcinoma: a proposal for standardization of quality care metrics. Cancers. 2022;14(7).","DOI":"10.3390\/cancers14071781"},{"key":"18411_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.05.010","volume":"42","author":"F Soria","year":"2022","unstructured":"Soria F, Pradere B, Hurle R, D\u2019Andrea D, Albisinni S, Diamand R, et al. Radical nephroureterectomy tetrafecta: a proposal reporting surgical strategy quality at surgery. Eur Urol Open Sci. 2022;42:1\u20138.","journal-title":"Eur Urol Open Sci."},{"issue":"1","key":"18411_CR15","doi-asserted-by":"publisher","DOI":"10.2196\/15363","volume":"9","author":"J Baard","year":"2020","unstructured":"Baard J, Celebi M, de la Rosette J, Alcaraz A, Shariat S, Cormio L, et al. Evaluation of patterns of presentation, practice, and outcomes of upper tract urothelial cancer: protocol for an observational, international, multicenter, cohort study by the clinical research office of the endourology society. JMIR Res Protoc. 2020;9(1):e15363.","journal-title":"JMIR Res Protoc."},{"key":"18411_CR16","unstructured":"Registry for Treatment of Upper Urinary Tract Tumours. NIH U.S. National Library of Medicine ClinicalTrials.gov."},{"key":"18411_CR17","unstructured":"Gliklich RE, Dreyer NA, Leavy MB (eds). Registries for Evaluating Patient Outcomes: A User's Guide. AHRQ Methods for Effective Health Care. 3rd ed. Rockville (MD); 2014."},{"issue":"11","key":"18411_CR18","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/iju.14068","volume":"26","author":"Y Honda","year":"2019","unstructured":"Honda Y, Nakamura Y, Teishima J, Goto K, Higaki T, Narita K, et al. Clinical staging of upper urinary tract urothelial carcinoma for T staging: review and pictorial essay. Int J Urol. 2019;26(11):1024\u201332.","journal-title":"Int J Urol."},{"issue":"4","key":"18411_CR19","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0022-5347(05)65194-4","volume":"167","author":"AM Meraney","year":"2002","unstructured":"Meraney AM, Gill IS. Financial analysis of open versus laparoscopic radical nephrectomy and nephroureterectomy. J Urol. 2002;167(4):1757\u201362.","journal-title":"J Urol."},{"issue":"1","key":"18411_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s12885-023-11058-z","volume":"23","author":"J Liu","year":"2023","unstructured":"Liu J, Wu P, Lai S, Wang J, Hou H, Zhang Y. Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning. BMC Cancer. 2023;23(1):574.","journal-title":"BMC Cancer."},{"issue":"2","key":"18411_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.euf.2018.09.007","volume":"6","author":"S Nazzani","year":"2020","unstructured":"Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Soulieres D, et al. Nephroureterectomy with or without Bladder Cuff excision for localized urothelial carcinoma of the renal pelvis. Eur Urol Focus. 2020;6(2):298\u2013304.","journal-title":"Eur Urol Focus."},{"issue":"11","key":"18411_CR22","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1245\/s10434-012-2453-9","volume":"19","author":"P Colin","year":"2012","unstructured":"Colin P, Ouzzane A, Yates DR, Audenet F, Pignot G, Arvin-Berod A, et al. Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival. Ann Surg Oncol. 2012;19(11):3613\u201320.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"18411_CR23","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S0022-5347(17)59324-6","volume":"115","author":"DW Strong","year":"1976","unstructured":"Strong DW, Pearse HD, Tank ES Jr, Hodges CV. The ureteral stump after nephroureterectomy. J Urol. 1976;115(6):654\u20135.","journal-title":"J Urol."},{"issue":"2","key":"18411_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.21037\/tau.2019.09.14","volume":"9","author":"RA Pathak","year":"2020","unstructured":"Pathak RA, Hemal AK. Fate of residual ureteral stump in patients undergoing robot-assisted radical nephroureterectomy for high-risk upper tract urothelial carcinoma. Transl Androl Urol. 2020;9(2):856\u201362.","journal-title":"Transl Androl Urol."},{"key":"18411_CR25","doi-asserted-by":"crossref","unstructured":"Slusarczyk A, Zapala P, Piecha T, Rajwa P, Moschini M, Radziszewski P. The Association between Lymph Node Dissection and Survival in Lymph Node-Negative Upper Urinary Tract Urothelial Cancer. Cancers. 2023;15(18).","DOI":"10.3390\/cancers15184660"},{"key":"18411_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.852969","volume":"9","author":"A Peyrottes","year":"2022","unstructured":"Peyrottes A, Califano G, Ouzaid I, Laine-Caroff P, Long Depaquit T, Hermieu JF, et al. Lymph node dissection during radical nephro-ureterectomy for upper tract urothelial carcinoma: a review. Front Surg. 2022;9:852969.","journal-title":"Front Surg."},{"key":"18411_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.731460","volume":"11","author":"CC Li","year":"2021","unstructured":"Li CC, Chang CH, Huang CP, Hong JH, Huang CY, Chen IA, et al. Comparing oncological outcomes and surgical complications of hand-assisted, laparoscopic and robotic nephroureterectomy for upper tract urothelial carcinoma. Front Oncol. 2021;11:731460.","journal-title":"Front Oncol."},{"issue":"2","key":"18411_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/end.2024.0730","volume":"39","author":"F Di Bello","year":"2025","unstructured":"Di Bello F, Rodriguez Penaranda N, Marmiroli A, Longoni M, Falkenbach F, Le QC, et al. In-hospital outcomes after robotic vs open radical nephroureterectomy. J Endourol. 2025;39(2):127\u201334.","journal-title":"J Endourol."},{"issue":"6","key":"18411_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2003.09.009","volume":"44","author":"L Salomon","year":"2003","unstructured":"Salomon L, Saint F, Anastasiadis AG, Sebe P, Chopin D, Abbou CC. Combined reporting of cancer control and functional results of radical prostatectomy. Eur Urol. 2003;44(6):656\u201360.","journal-title":"Eur Urol."},{"issue":"3","key":"18411_CR30","doi-asserted-by":"publisher","first-page":"e669","DOI":"10.1016\/j.clgc.2017.10.014","volume":"16","author":"M Ikeda","year":"2018","unstructured":"Ikeda M, Matsumoto K, Hirayama T, Koguchi D, Murakami Y, Matsuda D, et al. Selected high-risk patients with upper tract urothelial carcinoma treated with radical nephroureterectomy for adjuvant chemotherapy: a multi-institutional retrospective study. Clin Genitourin Cancer. 2018;16(3):e669\u201375.","journal-title":"Clin Genitourin Cancer."},{"issue":"10232","key":"18411_CR31","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268\u201377.","journal-title":"Lancet."},{"issue":"4","key":"18411_CR32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","volume":"60","author":"T O'Brien","year":"2011","unstructured":"O\u2019Brien T, Ray E, Singh R, Coker B, Beard R. British Association of urological surgeons section of O. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol. 2011;60(4):703\u201310.","journal-title":"Eur Urol."},{"issue":"4","key":"18411_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.eururo.2024.12.006","volume":"87","author":"T van Doeveren","year":"2025","unstructured":"van Doeveren T, Remmers S, Boeve ER, Cornel EB, van der Heijden AG, Hendricksen K, et al. Intravesical instillation of chemotherapy before radical surgery for upper urinary tract urothelial carcinoma: the REBACARE trial. Eur Urol. 2025;87(4):444\u201352.","journal-title":"Eur Urol."},{"issue":"12","key":"18411_CR34","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00345-015-1572-x","volume":"33","author":"A Aziz","year":"2015","unstructured":"Aziz A, Gierth M, Rink M, Schmid M, Chun FK, Dahlem R, et al. Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta. World J Urol. 2015;33(12):1945\u201350.","journal-title":"World J Urol."},{"issue":"1","key":"18411_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bju.14861","volume":"125","author":"GE Cacciamani","year":"2020","unstructured":"Cacciamani GE, Winter M, Medina LG, Ashrafi AN, Miranda G, Tafuri A, et al. Radical cystectomy pentafecta: a proposal for standardisation of outcomes reporting following robot-assisted radical cystectomy. BJU Int. 2020;125(1):64\u201372.","journal-title":"BJU Int."},{"issue":"5","key":"18411_CR36","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.eururo.2011.01.032","volume":"59","author":"VR Patel","year":"2011","unstructured":"Patel VR, Sivaraman A, Coelho RF, Chauhan S, Palmer KJ, Orvieto MA, et al. Pentafecta: a new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2011;59(5):702\u20137.","journal-title":"Eur Urol."},{"key":"18411_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/OTT.S225301","volume":"13","author":"JJ Leow","year":"2020","unstructured":"Leow JJ, Liu Z, Tan TW, Lee YM, Yeo EK, Chong YL. Optimal management of upper tract urothelial carcinoma: current perspectives. Onco Targets Ther. 2020;13:1\u201315.","journal-title":"Onco Targets Ther."},{"issue":"5","key":"18411_CR38","doi-asserted-by":"publisher","first-page":"774","DOI":"10.4103\/njcp.njcp_503_19","volume":"24","author":"M Yoldas","year":"2021","unstructured":"Yoldas M, Turk H, Yoldas TK. Clinical and pathological factors predictive of bladder cancer recurrence in patients with upper tract primary TCC. Niger J Clin Pract. 2021;24(5):774\u20137.","journal-title":"Niger J Clin Pract."},{"issue":"5","key":"18411_CR39","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.eururo.2012.02.042","volume":"61","author":"E Xylinas","year":"2012","unstructured":"Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat SF, et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol. 2012;61(5):1069\u201370.","journal-title":"Eur Urol."},{"issue":"5","key":"18411_CR40","doi-asserted-by":"publisher","first-page":"846","DOI":"10.21037\/tau-23-209","volume":"13","author":"TK O'Rourke Jr","year":"2024","unstructured":"O\u2019Rourke TK Jr, Thakker PU, Hemal AK. Refined step-by-step narrative review of robotic radical nephroureterectomy in the management of upper tract urothelial carcinoma. Transl Androl Urol. 2024;13(5):846\u201356.","journal-title":"Transl Androl Urol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18411-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18411-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18411-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T13:12:15Z","timestamp":1767618735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18411-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["18411"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18411-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ho-Ming Wong, Ivan Ching-Ho Ko, David Ka-Wai Leung, Kang Liu, Hongda Zhao, Steven Leung, Pilar Laguna, Jean de la Rosette, and Jeremy Yuen-Chun Teoh have no conflicts of interest to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}